Nampt Mediates Age-Associated Pro-Fibrotic Myofibroblast Phenotypes and Persistent Fibrosis

Technology #ua17-154

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Joe G.N. Garcia
Professor, Medicine
Louise Hecker
Assistant Professor, Medicine
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Title: Nampt Mediates Age-Associated Pro-Fibrotic Myofibroblast Phenotypes and Persistent Fibrosis

 

Invention: The invention is the targeting of nicotinamide phosphoribosyltransferase (Nampt) to protect from fibrosis, specifically as a new treatment target for idiopathic pulmonary fibrosis.

 

Background: In addition, an estimated 45% of deaths are attributed to disorders relating to fibrosis. Specifically, the most severe form of lung fibrosis is idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis is a fatal disease with a median survival rate of three years, affecting 200,000 people in the U.S. The disease is characterized by progressive scar tissue formation leading to respiratory failure. The risk factor of aging and the molecular mechanism involved in the pathogenesis of idiopathic pulmonary fibrosis is poorly understood and there is currently no treatment shown to improve the quality of life in idiopathic pulmonary fibrosis patients.

Applications:

  • Pharmaceuticals and therapeutics
  • Diagnostics

 

Advantages:

  • Regulation of lung fibrosis via a novel drug target
  • Potential diagnostic pathway to measure expression of Nampt and fibrotic lung injury

 

Licensing Manager:

Rakhi Gibbons

RakhiG@tla.arizona.edu

(520) 626-6695